On October 23, 2026, a clinical trial update was recorded for semaglutide, an approved compound. The trial, registered as NCT07891156 and titled "Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity," is listed as a Phase 2/3 study. Its current status is recruiting. The trial is designed to examine lean mass changes in adults who have both type 1 diabetes and overweight or obesity, according to the registration record. No results have been posted for this trial at this stage. The study remains open for participant enrollment under its listed phase classification. As with any trial in the recruiting stage, outcomes and findings are not yet available and should not be assumed. Further updates are expected as the trial progresses through its stated phases. Readers interested in background on semaglutide, including its approved uses and general profile, can consult the compound overview for additional context.
Semaglutide Trial on Lean Mass in Type 1 Diabetes Now Recruiting
See the full semaglutide overview
Source: https://clinicaltrials.gov/study/NCT07891156